| Basal cell carcinoma
Erivedge vs Odomzo
Side-by-side clinical, coverage, and cost comparison for basal cell carcinoma.Deep comparison between: Erivedge vs Odomzo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOdomzo has a higher rate of injection site reactions vs Erivedge based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Odomzo but not Erivedge, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Erivedge
Odomzo
At A Glance
Oral
Daily
Hedgehog pathway inhibitor
Oral
Daily
Hh pathway inhibitor
Indications
- Metastatic basal cell carcinoma
- Basal cell carcinoma
- Basal cell carcinoma
Dosing
Metastatic basal cell carcinoma, Basal cell carcinoma 150 mg orally once daily, with or without food, until disease progression or unacceptable toxicity; swallow capsules whole.
Basal cell carcinoma 200 mg orally once daily on an empty stomach, at least 1 hour before or 2 hours after a meal, until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) Muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, ageusia
Serious Embryo-fetal toxicity, severe cutaneous adverse reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), musculoskeletal adverse reactions, premature fusion of the epiphyses
Postmarketing Drug-induced liver injury, Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms
Most common (>=10%) Muscle spasms, alopecia, dysgeusia, fatigue, nausea, musculoskeletal pain, diarrhea, decreased weight, decreased appetite, myalgia, abdominal pain, headache, pain, vomiting, pruritus
Serious Musculoskeletal adverse reactions
Pharmacology
Vismodegib is an inhibitor of the Hedgehog pathway that binds to and inhibits Smoothened, a transmembrane protein involved in Hedgehog signal transduction.
Sonidegib is an Hh pathway inhibitor that binds to and inhibits Smoothened, a transmembrane protein involved in Hh signal transduction.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Erivedge
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Odomzo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Erivedge
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (4/8)
Odomzo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Erivedge
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Odomzo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Metastatic Skin Cancer - Non Melanoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$10/momo
Odomzo Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ErivedgeView full Erivedge profile
OdomzoView full Odomzo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.